A comparison between Bromocriptine and Selegiline in treatment of Parkinsons disease

Background and Objective: Parkinson is a common disease that caused by degeneration of nigrostriatal dopaminergic pathways. Drug therapy can prevent movement disorders in patients and so they can do independently their daily activities. Many drugs are used for treatment for this disease. This study...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	A Ahmadi Ahangar, SAR Sadraei Mousavi
Formato:	article
Lenguaje:	EN FA
Publicado:	Babol University of Medical Sciences 2002
Materias:	parkinsons disease dyskinesia levodopa selegiline bromocriptine Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/e0dce7db8d0d468cbc7fe0c6d59d79af
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e0dce7db8d0d468cbc7fe0c6d59d79af
record_format	dspace
spelling	oai:doaj.org-article:e0dce7db8d0d468cbc7fe0c6d59d79af2021-11-10T09:19:40ZA comparison between Bromocriptine and Selegiline in treatment of Parkinsons disease1561-41072251-7170https://doaj.org/article/e0dce7db8d0d468cbc7fe0c6d59d79af2002-07-01T00:00:00Zhttp://jbums.org/article-1-2817-en.htmlhttps://doaj.org/toc/1561-4107https://doaj.org/toc/2251-7170Background and Objective: Parkinson is a common disease that caused by degeneration of nigrostriatal dopaminergic pathways. Drug therapy can prevent movement disorders in patients and so they can do independently their daily activities. Many drugs are used for treatment for this disease. This study was done to compare the effect of bromocriptine and selegiline in Parkinsons disease. Methods: 77 outpatients (50 were male and 27 were female) with the mean age of 65 years were selected and followed for a three year period. The patients were divided into three groups: Levodopa and trithexyphenidyl were administered to all groups but in second and third groups they were given selegiline and bromocriptine, respectively. The patients were evaluated on the basis of United Parkinsons Disease Rate Scale (UPDRS) and consequent visits. Findings: In this study by considering motor scale, third group in comparison to first group was in a better condition. At first, second group (Selegiline) in comparison to first group was in a better condition but by passing a period of time this difference was statistically non-significant. The rate of side effects especially dyskinesia in third group was low. Conclusion: According to the results, bromocriptine as an adjunctive drug is used for treatment of Parkinsons disease with levodopa and in comparison to selegiline is more effective.A Ahmadi AhangarSAR Sadraei MousaviBabol University of Medical Sciencesarticleparkinsons diseasedyskinesialevodopaselegilinebromocriptineMedicineRMedicine (General)R5-920ENFAMajallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, Vol 4, Iss 3, Pp 18-22 (2002)
institution	DOAJ
collection	DOAJ
language	EN FA
topic	parkinsons disease dyskinesia levodopa selegiline bromocriptine Medicine R Medicine (General) R5-920
spellingShingle	parkinsons disease dyskinesia levodopa selegiline bromocriptine Medicine R Medicine (General) R5-920 A Ahmadi Ahangar SAR Sadraei Mousavi A comparison between Bromocriptine and Selegiline in treatment of Parkinsons disease
description	Background and Objective: Parkinson is a common disease that caused by degeneration of nigrostriatal dopaminergic pathways. Drug therapy can prevent movement disorders in patients and so they can do independently their daily activities. Many drugs are used for treatment for this disease. This study was done to compare the effect of bromocriptine and selegiline in Parkinsons disease. Methods: 77 outpatients (50 were male and 27 were female) with the mean age of 65 years were selected and followed for a three year period. The patients were divided into three groups: Levodopa and trithexyphenidyl were administered to all groups but in second and third groups they were given selegiline and bromocriptine, respectively. The patients were evaluated on the basis of United Parkinsons Disease Rate Scale (UPDRS) and consequent visits. Findings: In this study by considering motor scale, third group in comparison to first group was in a better condition. At first, second group (Selegiline) in comparison to first group was in a better condition but by passing a period of time this difference was statistically non-significant. The rate of side effects especially dyskinesia in third group was low. Conclusion: According to the results, bromocriptine as an adjunctive drug is used for treatment of Parkinsons disease with levodopa and in comparison to selegiline is more effective.
format	article
author	A Ahmadi Ahangar SAR Sadraei Mousavi
author_facet	A Ahmadi Ahangar SAR Sadraei Mousavi
author_sort	A Ahmadi Ahangar
title	A comparison between Bromocriptine and Selegiline in treatment of Parkinsons disease
title_short	A comparison between Bromocriptine and Selegiline in treatment of Parkinsons disease
title_full	A comparison between Bromocriptine and Selegiline in treatment of Parkinsons disease
title_fullStr	A comparison between Bromocriptine and Selegiline in treatment of Parkinsons disease
title_full_unstemmed	A comparison between Bromocriptine and Selegiline in treatment of Parkinsons disease
title_sort	comparison between bromocriptine and selegiline in treatment of parkinsons disease
publisher	Babol University of Medical Sciences
publishDate	2002
url	https://doaj.org/article/e0dce7db8d0d468cbc7fe0c6d59d79af
work_keys_str_mv	AT aahmadiahangar acomparisonbetweenbromocriptineandselegilineintreatmentofparkinsonsdisease AT sarsadraeimousavi acomparisonbetweenbromocriptineandselegilineintreatmentofparkinsonsdisease AT aahmadiahangar comparisonbetweenbromocriptineandselegilineintreatmentofparkinsonsdisease AT sarsadraeimousavi comparisonbetweenbromocriptineandselegilineintreatmentofparkinsonsdisease
_version_	1718440148935376896

A comparison between Bromocriptine and Selegiline in treatment of Parkinsons disease

Ejemplares similares